<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/86BA0D2C-1895-41C5-B18C-092178DFFB3E"><gtr:id>86BA0D2C-1895-41C5-B18C-092178DFFB3E</gtr:id><gtr:name>National Institute for Health Research</gtr:name><gtr:address><gtr:line1>NIHR Clinical Research Network CC</gtr:line1><gtr:line2>Fairbairn House</gtr:line2><gtr:line3>71-75 Clarendon Road</gtr:line3><gtr:postCode>LS2 9PH</gtr:postCode><gtr:region>Yorkshire and the Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F7E13617-2678-475B-99E4-31479C92038D"><gtr:id>F7E13617-2678-475B-99E4-31479C92038D</gtr:id><gtr:name>University of Aberdeen</gtr:name><gtr:address><gtr:line1>University Office</gtr:line1><gtr:line2>Regent Walk</gtr:line2><gtr:line4>Aberdeen</gtr:line4><gtr:line5>Aberdeenshire</gtr:line5><gtr:postCode>AB24 3FX</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B8315305-3AE0-4833-BCEF-0539D3B31074"><gtr:id>B8315305-3AE0-4833-BCEF-0539D3B31074</gtr:id><gtr:name>Gilead</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8218E276-85FA-4CD5-86AA-232A830B5037"><gtr:id>8218E276-85FA-4CD5-86AA-232A830B5037</gtr:id><gtr:name>University of Texas at San Antonio</gtr:name><gtr:address><gtr:line1>One UTSA Circle</gtr:line1><gtr:line4>San Antonio</gtr:line4><gtr:line5>TX 78249-1644</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/19D01239-9063-4914-9D02-3D494BE14627"><gtr:id>19D01239-9063-4914-9D02-3D494BE14627</gtr:id><gtr:name>Royal Brompton &amp; Harefield NHS Foundation Trust</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Dept of Medicine</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/86BA0D2C-1895-41C5-B18C-092178DFFB3E"><gtr:id>86BA0D2C-1895-41C5-B18C-092178DFFB3E</gtr:id><gtr:name>National Institute for Health Research</gtr:name><gtr:address><gtr:line1>NIHR Clinical Research Network CC</gtr:line1><gtr:line2>Fairbairn House</gtr:line2><gtr:line3>71-75 Clarendon Road</gtr:line3><gtr:postCode>LS2 9PH</gtr:postCode><gtr:region>Yorkshire and the Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F7E13617-2678-475B-99E4-31479C92038D"><gtr:id>F7E13617-2678-475B-99E4-31479C92038D</gtr:id><gtr:name>University of Aberdeen</gtr:name><gtr:address><gtr:line1>University Office</gtr:line1><gtr:line2>Regent Walk</gtr:line2><gtr:line4>Aberdeen</gtr:line4><gtr:line5>Aberdeenshire</gtr:line5><gtr:postCode>AB24 3FX</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B8315305-3AE0-4833-BCEF-0539D3B31074"><gtr:id>B8315305-3AE0-4833-BCEF-0539D3B31074</gtr:id><gtr:name>Gilead</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8218E276-85FA-4CD5-86AA-232A830B5037"><gtr:id>8218E276-85FA-4CD5-86AA-232A830B5037</gtr:id><gtr:name>University of Texas at San Antonio</gtr:name><gtr:address><gtr:line1>One UTSA Circle</gtr:line1><gtr:line4>San Antonio</gtr:line4><gtr:line5>TX 78249-1644</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/19D01239-9063-4914-9D02-3D494BE14627"><gtr:id>19D01239-9063-4914-9D02-3D494BE14627</gtr:id><gtr:name>Royal Brompton &amp; Harefield NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6F9C2EB5-08F0-47C1-8E91-CF7E814548B6"><gtr:id>6F9C2EB5-08F0-47C1-8E91-CF7E814548B6</gtr:id><gtr:firstName>Darius</gtr:firstName><gtr:surname>Armstrong-James</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0902260"><gtr:id>64223051-2468-4DA5-8360-9D321E487FF0</gtr:id><gtr:title>A novel immuno-diagnostic strategy for invasive fungal infections in solid organ transplant patients.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0902260</gtr:grantReference><gtr:abstractText>The drugs used in patients who have organ transplants stop the immune system rejecting the transplant. However, they also impair the immune system?s response to infection. A major problem for these patients is they become susceptible to life-threatening invasive fungal infections (IFIs). 
My pilot studies in renal transplant patients indicate these infections may be due to deficiency of an immune-system activating chemical called interferon- . Furthermore I found that treating IFIs in transplant patients with interferon- injections may dramatically improve their chance of survival.
I now propose to define the mechanisms by which transplant drugs lead to susceptibility to IFIs in a mouse mouse model of invasive fungal infection where the mouse are treated with the same transplant drugs. This will enable me to understand how these immune deficits occur, and develop new diagnostic assays to be tested in parallel clinical studies in renal transplant patients with IFIs.
These studies will lead to the delivery of novel diagnostic assays to identify patients at risk of these infections and identify those patients with IFIs who can benefit from life saving interferon- therapy. It is further anticipated these diagnostic assays could have wider application to many infectious diseases in the future.</gtr:abstractText><gtr:technicalSummary>Key aims and objectives of the project
1) Define the effects of transplant immuno-suppressant drugs on host immunity in the standard hydrocortisone-suppressed (HC) murine model of invasive aspergillosis (IA).
2) Identify the immune deficits that lead to susceptibility to IA in this model.
3) Develop novel diagnostic assays of susceptibility to invasive fungal infections in this model.
4) Validate these diagnostic assays through synergistic studies in renal transplant patients.
Design and Methodology
1) Define the additive effects of the transplant immuno-suppressants tacrolimus (FK506) and mycophenolate (MMF) on mortality in the HC-based model of invasive aspergillosis. Doses of FK506 and MMF will be increased until mortality increases from 50% to &amp;gt;80%. The model will be defined through histopathologiocal, pharmocokinetic, fungal burden and peripheral blood profiling. 
2) Identify the key defects in immunity that increase susceptibility to IA in this model. Macrophage, T lymphocyte, NKT cell and dendritic cell populations, function and fungal responses in lung, liver, spleen and peripheral blood will be characterized by conidial phagocytosis assays, RT-PCR and Luminex cytokine assay, FACS analysis, NKT cell xenogenic target assays, and dendritic cell na?ve T-cell co-culture. 
3) Develop peripheral blood mononuclear cell (PBMC) microarray and anti-Aspergillus T-cell Elispot IFN- assays that identify increased susceptibility to IA in FK506/MMF-immuno-suppressed mice. PBMCs from infected mice will be stimulated with Aspergillus antigens or control mitogens. Cytokine responses will be assayed by Agilent whole genome microarrays and correlated with immuno-suppressive drug levels and transcriptional markers of drug toxicity. Parallel anti-Aspergillus T-cell IFN- Elispot assays will be performed on peripheral blood. The Elispot assay will provide a highly sensitive means of quantifying the effects of FK506/MMF on T-cell mediated antifungal immunity.
4) Define the utility of the PBMC RT-PCR and Elispot assays described in Component 3 through a controlled clinical study of 40 renal transplant patients with invasive fungal infections. For the PBMC assays, select markers of susceptibility to invasive fungal infection will be translated into a rapid RT-PCR assay that can also identify patients who will benefit from IFN- therapy. 
Scientific and Medical Opportunities
1) Deliver a model in which to define the immuno-pathogenesis of transplant infectious diseases.
2) Identify of the key immunological defects that predispose solid organ transplant patients to IFIs.
3) Deliver peripheral blood assays to identify susceptibility to IFI and guide immuno-therapy.
4) Provide a rational basis for future studies of biopharmaceutical modulators for IFIs.</gtr:technicalSummary><gtr:fund><gtr:end>2014-10-05</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-10-06</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>842000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Brompton &amp; Harefield NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Heart and Lung Transplantation Unit</gtr:department><gtr:description>Innate antifungal responses in lung transplant recipients</gtr:description><gtr:id>C69BEE38-56A7-463B-9F1B-5E688207FC1E</gtr:id><gtr:impact>Paper in review, Disease Models and Mechanisms</gtr:impact><gtr:outcomeId>Yb3Bsb8wWUK-1</gtr:outcomeId><gtr:partnerContribution>I receive BAL samples from the Harefield, who also consent patients and have helped with relevant ethical permissions.</gtr:partnerContribution><gtr:piContribution>We are analysing innate immune responses in alveolar macrophages from lung transplant recipients attending the Harefield Hospital</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Texas</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>NK cell immunotherapy for aspergillosis</gtr:description><gtr:id>C6F4BC39-57DA-4ABC-B3EE-16FE8655E7C9</gtr:id><gtr:impact>Establishment of NK cell research within my laboratory.</gtr:impact><gtr:outcomeId>bZeqYmvXwaz-1</gtr:outcomeId><gtr:partnerContribution>Dr Rezvani funds one of the students, Tak Sekine, who is 50:50 between MD Anderson and Imperial, but registered through Imperial College London.</gtr:partnerContribution><gtr:piContribution>I have two shared PhD students with Katy Rezvani, head of stem cell transplant research, at MD Anderson, the worlds largest stem cell transplant hospital. Our students are working on the role of NK cells in Aspergillosis and thier utility in cord blood transplantation and antifungal immunotherapy. I hope the collaboration will lead to major stdies of NK therapy for infectious diseases in immunocompromised hosts.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute for Health Research</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>NIHR Imperial Biomedical Research Centre</gtr:department><gtr:description>Fungal diagnostics in high-risk patients</gtr:description><gtr:id>68FD195D-B1BC-4F07-9697-6FC7D310EDBA</gtr:id><gtr:impact>This has enabled improved diagnostics for patients in West London</gtr:impact><gtr:outcomeId>5460ebb8c69372.55764584-1</gtr:outcomeId><gtr:partnerContribution>Finincial support from the Imperial BRC and research infrastructure support from the Centre for Haematology</gtr:partnerContribution><gtr:piContribution>Facilitation of a randomised study of fungal diagnostics in high risk patients</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Aberdeen</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Medical Sciences Aberdeen</gtr:department><gtr:description>Wellcome Trust Strategic Award in Medical Mycology and Fungal Immunology Clinical Research Fellowship</gtr:description><gtr:id>0DDB5BF6-7345-496B-B240-2767032E815C</gtr:id><gtr:impact>PhD Clinical Fellowship as described.</gtr:impact><gtr:outcomeId>5460f8c9c4a298.74584653-1</gtr:outcomeId><gtr:partnerContribution>Collaboration with Adilia Warris at Aberdeen who will collaborate on innate immunity in cystic fibrosis with clinical samples and intellectual input/co-supervision</gtr:partnerContribution><gtr:piContribution>Award of a clinical PhD fellowship to Amelia Bercussson to study innate immunity to fungi in cystic fibrosis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Gilead</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Genomic sequencing of azole-resistant Aspergillus fumigates</gtr:description><gtr:id>F12929CD-DF4D-4119-A0E4-CB7EEB6CA381</gtr:id><gtr:impact>mBio paper &amp;quot;genomic context of azalea resistance in Aspergillus fumigates&amp;quot; as detailed in publications</gtr:impact><gtr:outcomeId>56dd4862edc1b3.60935581-1</gtr:outcomeId><gtr:partnerContribution>financial contribution</gtr:partnerContribution><gtr:piContribution>Genome sequencing</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Royal Society Summer Exhibition &quot;Killer Fungus&quot;</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>94A03AEC-EB28-4FD4-9EA3-3A5F308A5D1B</gtr:id><gtr:impact>A public outreach stall in the RSSE organised by the UK Mycology community (lead Aberdeen, Neil Gow).</gtr:impact><gtr:outcomeId>58c6bd69ef99e4.40774736</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://royalsociety.org/science-events-and-lectures/summer-science-exhibition/exhibits/killer-fungus/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Engagement for research with local Renal transplant patients group</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>DDD2BA8D-B713-46DD-89FB-366011EB1932</gtr:id><gtr:impact>I am awaiting feedback from the Wets London Renal transplant Patients group and will give them a talk

DISSEMINATION OF INFORMATION ON PATIENT RESEARCH TO INVOLVED PATIENTS</gtr:impact><gtr:outcomeId>546240c7b04434.38384422</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Imperial College Academic Health Science Centre</gtr:department><gtr:description>Imperial College Academic Health Science Centre Biomedical Research Centre</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>Imperial College London</gtr:fundingOrg><gtr:id>CA0AE83E-DAB8-4AB6-866A-6A11C3D05278</gtr:id><gtr:outcomeId>54623fb380bee1.11833579</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>105000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>British Society of Antimicrobial Chemotherapy PhD Studentship</gtr:description><gtr:end>2015-04-02</gtr:end><gtr:fundingOrg>British Society for Antimicrobial Chemotherapy</gtr:fundingOrg><gtr:id>F41E423D-F463-49BB-9F2E-1C7CC9E9FCF9</gtr:id><gtr:outcomeId>bt1XEV2fzjT</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>20000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Grant</gtr:description><gtr:end>2019-10-02</gtr:end><gtr:fundingOrg>Natural Environment Research Council</gtr:fundingOrg><gtr:fundingRef>NE/P001165/1</gtr:fundingRef><gtr:id>10032A14-C0B3-4AEB-B10A-7F9037D3AB8B</gtr:id><gtr:outcomeId>58c6b4f505dc00.55932157</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>240000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Clinical Research Fellow</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>1862E386-5799-4BDC-AC57-AB5E4C49AB9D</gtr:id><gtr:outcomeId>LJhiCB69ugF</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Seed Award in Science</gtr:description><gtr:end>2018-05-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>204566/Z/16/Z</gtr:fundingRef><gtr:id>E262C9B7-C815-4668-8749-8C810EA5742E</gtr:id><gtr:outcomeId>58c6b56bd5ba94.67980433</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Centenary Award</gtr:description><gtr:end>2013-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>14BF7AD6-0CAA-4D2A-BF00-8D017687BCD8</gtr:id><gtr:outcomeId>AR1fE1HGjTU</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>215000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Wellcome Trust Strategic Award</gtr:department><gtr:description>Wellcome Trust Strategic Award in Medical Mycology and Fungal Immunology</gtr:description><gtr:end>2018-01-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>2BE1A213-E448-4ED2-B446-A57D9F2646B2</gtr:id><gtr:outcomeId>54623f4a81a631.06106241</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>ISHAM Working Party on HIV Mycoses</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>471C7A17-7C9D-439B-8489-01CFFC45711C</gtr:id><gtr:outcomeId>RkRYAPuCcri</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member, European Fungal Infection Study Group</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>FAF87BFA-1AA9-44C4-8DAF-2A4AB8BC2B16</gtr:id><gtr:outcomeId>54624678e84589.44563305</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type><gtr:url>https://www.escmid.org/research_projects/study_groups/fungal_infection/</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>ISHAM Working Party on Fungal Respiratory Infections in Cystic Fibrosis</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>475BE61B-A75C-404A-9148-78168CD9806F</gtr:id><gtr:outcomeId>5462472f7e7543.86493299</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type><gtr:url>http://www.isham.org/WorkingGroups/CysticFibrosis/</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>A new Aspergillus point of care assay (Chris Thornton, University of exeter) has been validated in lung transplant recipients at risk of invasive aspergillosis</gtr:description><gtr:id>1F57F0C7-2C8E-4D87-9619-2539FB0C28CF</gtr:id><gtr:impact>Improved case definition leading to better research outcomes</gtr:impact><gtr:outcomeId>546248b10be762.15902735</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Development of diagnostic algorithms for fungal infection in lung transplant recipients</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:url>http://www.iscadiagnostics.com/products/aspergillosis-flow-device/</gtr:url><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>deposited in european nucleotide database.isolates deposited in NIAID Aspergillus repository</gtr:description><gtr:id>B4B99F72-1ADA-4C74-AE7C-B853044D7377</gtr:id><gtr:impact>other groups are working on these isolates in the context of various virulence traits</gtr:impact><gtr:outcomeId>56dd4bd53c5764.14541993</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>24 Aspergillus fumigates genomes</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We developed novel real-time confocal imaging approaches to show that macrophages transfer Aspergillus fumigatus between them during macrophage cell death and have set up the assays in transgenic zebrafish lines</gtr:description><gtr:id>571D62A1-BEA5-47F2-AB88-2A0E15E1C633</gtr:id><gtr:impact>We have described a entirely novel form of macrophage cell death, which is cell to cell host mediated transfer of a pathogen i.e. Aspergillus fumigatus, and devloped the techniques to measure this. The work was publisghed in 2016 in the American Journal of Respiratory and critical care Medicine, the leading respiratory journal.</gtr:impact><gtr:outcomeId>58c6bef45efcd3.40375973</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Single cell imaging of fungal induce macrophage cell death</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>http://www.atsjournals.org/doi/abs/10.1164/rccm.201601-0070OC?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%3dpubmed</gtr:url><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Next generation sequencing of Aspergillus fumigates and phylogenetic analysis of global population structure as detailed in &amp;quot;genomic context of amole-resistant Aspergillus fumigatus&amp;quot; publication</gtr:description><gtr:id>813373A5-3F4B-405F-A554-AFCFBBD12CF5</gtr:id><gtr:impact>we made the isolate collection globally available and several groups are now working on it with the benefit of the genome sequences</gtr:impact><gtr:outcomeId>56dd4b67c54d23.48918718</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Aspergillus high-throughput genome sequencing and phylogenetic analysis</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have performed extensive pharmakokinetic studies to determine the ideal dosing regimens for FK506 and mycophenolate to render mice susceptible to invasive aspergillosis</gtr:description><gtr:id>92CC76E5-E9A5-4111-BE7D-E2F361F5A021</gtr:id><gtr:impact>Greater understanding of the immunological factors that predispose to invasive aspergillosis in transplantation</gtr:impact><gtr:outcomeId>fpxG6j8QvDJ</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Transplant immunosuppression model for invasive aspergillosis</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A new model of zebrafish hind brain invasive aspergillosis in which shows that calcineurin inhibitors impair neutrophil recruitment to the site of infection leading to increased mortality</gtr:description><gtr:id>8477122D-7226-4765-8CA7-E3D4DBB5689C</gtr:id><gtr:impact>We are publishing a paper hopefully soon on this</gtr:impact><gtr:outcomeId>546247a3c63279.17105208</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Zebrafish model for transplant aspergillosis</gtr:title><gtr:type>Model of mechanisms or symptoms - non-mammalian in vivo</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>4708CA9B-DF40-4B66-AAB6-3CCD4279913E</gtr:id><gtr:title>Renal allograft recipients fail to increase interferon-? during invasive fungal diseases.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1bcaf5967d9e114942c20e54388995f"><gtr:id>f1bcaf5967d9e114942c20e54388995f</gtr:id><gtr:otherNames>Armstrong-James D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>pm_13390_20_22974244</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC77C843-E750-49F8-8F97-E5DFEAE94367</gtr:id><gtr:title>The serum opsonin L-ficolin is detected in lungs of human transplant recipients following fungal infections and modulates inflammation and killing of Aspergillus fumigatus.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f1c82c07af7e118f8a69309cea85be4"><gtr:id>8f1c82c07af7e118f8a69309cea85be4</gtr:id><gtr:otherNames>Bidula S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>56dd455de0f005.47922897</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2BB8DE6-5936-4082-9A9E-D21423C40EE1</gtr:id><gtr:title>Calcineurin Orchestrates Lateral Transfer of Aspergillus fumigatus during Macrophage Cell Death.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/35233ed9adaf19841a3034fd01bb9467"><gtr:id>35233ed9adaf19841a3034fd01bb9467</gtr:id><gtr:otherNames>Shah A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>585d64a3d4a694.69634593</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3A85448-6AF8-4298-BC95-FD84679E9B3B</gtr:id><gtr:title>Caspofungin Increases Fungal Chitin and Eosinophil and ?d T Cell-Dependent Pathology in Invasive Aspergillosis.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cbcdf0fb0bda219466a1f1739d03493c"><gtr:id>cbcdf0fb0bda219466a1f1739d03493c</gtr:id><gtr:otherNames>Amarsaikhan N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>5a578c3f661369.49523418</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A8F0F536-03B9-4484-AFDC-CA9AF0548E8D</gtr:id><gtr:title>Burden of serious fungal infections in Mexico.</gtr:title><gtr:parentPublicationTitle>Mycoses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/438f3ac4484a3df46f3aa519dcf85eb8"><gtr:id>438f3ac4484a3df46f3aa519dcf85eb8</gtr:id><gtr:otherNames>Corzo-Le?n DE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0933-7407</gtr:issn><gtr:outcomeId>56dd455e1e34a5.43374060</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3D1FA4F6-6991-4076-9606-A4F8236CEFB5</gtr:id><gtr:title>Genomic Context of Azole Resistance Mutations in Aspergillus fumigatus Determined Using Whole-Genome Sequencing.</gtr:title><gtr:parentPublicationTitle>mBio</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/881f0dc661d09f321806e0708336a550"><gtr:id>881f0dc661d09f321806e0708336a550</gtr:id><gtr:otherNames>Abdolrasouli A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56dd455f133631.90463041</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D5A52D18-785B-4C42-B247-94600793F832</gtr:id><gtr:title>AIDS-related mycoses: the way forward.</gtr:title><gtr:parentPublicationTitle>Trends in microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e9e7670819526636d49a136b653addc7"><gtr:id>e9e7670819526636d49a136b653addc7</gtr:id><gtr:otherNames>Brown GD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0966-842X</gtr:issn><gtr:outcomeId>5460eab7e30fb2.39854817</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF2734F7-DCA8-4A0E-B767-5E58A3A26CC6</gtr:id><gtr:title>Nebulised amphotericin B-polymethacrylic acid nanoparticle prophylaxis prevents invasive aspergillosis.</gtr:title><gtr:parentPublicationTitle>Nanomedicine : nanotechnology, biology, and medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/34ed39c323d99c5940c94220e6fa61c7"><gtr:id>34ed39c323d99c5940c94220e6fa61c7</gtr:id><gtr:otherNames>Shirkhani K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1549-9634</gtr:issn><gtr:outcomeId>56dd455e42c3c7.34037628</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7658FA9F-38CC-4D23-BDCB-CC803E76C2BB</gtr:id><gtr:title>Transcript profiling of the murine immune response to invasive aspergillosis.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/215553f18ea3976cf041d8d6c206f9c5"><gtr:id>215553f18ea3976cf041d8d6c206f9c5</gtr:id><gtr:otherNames>Dhesi Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>pm_13390_20_22328393</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>78E269DB-3C14-4D5B-8CD6-B2FEE6CFC1D4</gtr:id><gtr:title>Correction: The pH-Responsive PacC Transcription Factor of Aspergillus fumigatus Governs Epithelial Entry and Tissue Invasion during Pulmonary Aspergillosis.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2988254a9ac0033de46fe5b05392a53e"><gtr:id>2988254a9ac0033de46fe5b05392a53e</gtr:id><gtr:otherNames>Bertuzzi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>585d6302eecda5.95707905</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>974A0930-0AF1-456B-B481-16D1EE4F0962</gtr:id><gtr:title>Phagocytosis-dependent activation of a TLR9-BTK-calcineurin-NFAT pathway co-ordinates innate immunity to Aspergillus fumigatus.</gtr:title><gtr:parentPublicationTitle>EMBO molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a72830ea0c2b656d2b69838ea5d4bae7"><gtr:id>a72830ea0c2b656d2b69838ea5d4bae7</gtr:id><gtr:otherNames>Herbst S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1757-4676</gtr:issn><gtr:outcomeId>5675df37e4d68</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8440979C-3D88-47DB-979F-2A1AFC062926</gtr:id><gtr:title>A new and clinically relevant murine model of solid-organ transplant aspergillosis.</gtr:title><gtr:parentPublicationTitle>Disease models &amp; mechanisms</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a72830ea0c2b656d2b69838ea5d4bae7"><gtr:id>a72830ea0c2b656d2b69838ea5d4bae7</gtr:id><gtr:otherNames>Herbst S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1754-8403</gtr:issn><gtr:outcomeId>pm_13390_20_23264562</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E32EAC7-290A-4CA3-8806-092080AF891D</gtr:id><gtr:title>Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0dc6c7d6156f3c8548b9d4c8b4e68016"><gtr:id>0dc6c7d6156f3c8548b9d4c8b4e68016</gtr:id><gtr:otherNames>Sekine T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>585d6194dd5cb4.48763194</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>24CD81CC-52EF-47E3-8BD3-CB023F66CBCC</gtr:id><gtr:title>H-ficolin binds Aspergillus fumigatus leading to activation of the lectin complement pathway and modulation of lung epithelial immune responses.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f1c82c07af7e118f8a69309cea85be4"><gtr:id>8f1c82c07af7e118f8a69309cea85be4</gtr:id><gtr:otherNames>Bidula S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>5675e7a8389d1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>234EECBF-DB43-4F58-8DDD-B907230C1D79</gtr:id><gtr:title>Immunotherapy for fungal infections.</gtr:title><gtr:parentPublicationTitle>Current opinion in microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1bcaf5967d9e114942c20e54388995f"><gtr:id>f1bcaf5967d9e114942c20e54388995f</gtr:id><gtr:otherNames>Armstrong-James D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1369-5274</gtr:issn><gtr:outcomeId>pm_13390_20_22884572</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D57D9AC2-1F8A-41B8-84CB-39511780B9B9</gtr:id><gtr:title>The pH-responsive PacC transcription factor of Aspergillus fumigatus governs epithelial entry and tissue invasion during pulmonary aspergillosis.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2988254a9ac0033de46fe5b05392a53e"><gtr:id>2988254a9ac0033de46fe5b05392a53e</gtr:id><gtr:otherNames>Bertuzzi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>5460eab81546b5.27168775</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>618B1D68-3093-4C7D-A744-69D9F1036ED1</gtr:id><gtr:title>From phagocytosis to metaforosis: Calcineurin's deadly role in innate processing of fungi.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1bcaf5967d9e114942c20e54388995f"><gtr:id>f1bcaf5967d9e114942c20e54388995f</gtr:id><gtr:otherNames>Armstrong-James D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>5aa65fe7d14fe7.47206096</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E73671B-081C-4E84-A182-AF33F8545029</gtr:id><gtr:title>Staphylococcus aureus adapts to oxidative stress by producing H2O2-resistant small-colony variants via the SOS response.</gtr:title><gtr:parentPublicationTitle>Infection and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/64b00c21ec732fb8aada9215f4e73931"><gtr:id>64b00c21ec732fb8aada9215f4e73931</gtr:id><gtr:otherNames>Painter KL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0019-9567</gtr:issn><gtr:outcomeId>56dd455e7410b9.07388013</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B75AE17-5B8E-4174-A92E-9BC868139A0F</gtr:id><gtr:title>A neglected epidemic: fungal infections in HIV/AIDS.</gtr:title><gtr:parentPublicationTitle>Trends in microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1bcaf5967d9e114942c20e54388995f"><gtr:id>f1bcaf5967d9e114942c20e54388995f</gtr:id><gtr:otherNames>Armstrong-James D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0966-842X</gtr:issn><gtr:outcomeId>5460eab7be23f2.69294478</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>821775D5-14CC-411D-A8C6-43DECD295192</gtr:id><gtr:title>In silico modeling of spore inhalation reveals fungal persistence following low dose exposure.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/84474449c0d58f1a34e457b07357da76"><gtr:id>84474449c0d58f1a34e457b07357da76</gtr:id><gtr:otherNames>Tanaka RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>56dd455ecc90d8.34456858</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0902260</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>75</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>